Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.
- DOI
- 10.1016/s1470-2045(22)00452-1
- Published
- 2022 Sep
- Container
- The Lancet. Oncology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
serious concern Score 0/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- serious concernRetraction Watch retraction: 1 retraction notice matched this DOI.
- serious concernRetraction Watch expression of concern: 1 expression of concern notice matched this DOI.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s1470-2045-22-00452-1,
title = {Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.},
author = {Dummer R and Queirolo P and Abajo Guijarro AM and Hu Y and Wang D and de Azevedo SJ and Robert C and Ascierto PA and Chiarion-Sileni V and Pronzato P and Spagnolo F and Mujika Eizmendi K and Liszkay G and de la Cruz Merino L and Tawbi H},
year = {2022},
journal = {The Lancet. Oncology},
doi = {10.1016/s1470-2045(22)00452-1},
url = {https://doi.org/10.1016/s1470-2045(22)00452-1}
}RIS
TY - JOUR TI - Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study. AU - Dummer R AU - Queirolo P AU - Abajo Guijarro AM AU - Hu Y AU - Wang D AU - de Azevedo SJ AU - Robert C AU - Ascierto PA AU - Chiarion-Sileni V AU - Pronzato P AU - Spagnolo F AU - Mujika Eizmendi K AU - Liszkay G AU - de la Cruz Merino L AU - Tawbi H PY - 2022 JO - The Lancet. Oncology DO - 10.1016/s1470-2045(22)00452-1 UR - https://doi.org/10.1016/s1470-2045(22)00452-1 ER -
APA
R, D., P, Q., AM, A. G., Y, H., D, W., SJ, D. A., C, R., PA, A., V, C., P, P., F, S., K, M. E., G, L., L, D. L. C. M., & H, T. (2022). Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(22)00452-1
Source records
- pubmed · retrieved 2026-09-26T18:23:54.715Z